The Merck story

What drives the business

• Keytruda anchors Merck’s business through approvals across numerous cancers and treatment settings, with growth in the quarter to June 2026 supported by earlier-stage uses and demand in metastatic disease.
• The Pharmaceutical segment encompasses prescription medicines and human vaccines, while Animal Health serves livestock and companion animals and generated $1.8 billion in sales, up 8%, in the quarter to June 2026.
• Keytruda Qlex, administered under the skin, contributed $463 million in the quarter to June 2026, while pulmonary arterial hypertension medicine Winrevair benefited from continued U.S. uptake and launches in Japan and Europe.
• Merck’s expansion beyond Keytruda includes the $10.4 billion acquisition of Verona Pharma, which brought Ohtuvayre, and the $6.8 billion acquisition of Terns, which added investigational leukemia medicine MK-4208.
• Lipfendra’s approval adds an oral cholesterol treatment, while collaborations with Kelun-Biotech on sac-TMT and Gilead on a weekly oral HIV regimen extend Merck’s development portfolio.

What the price assumes

At $148.69, the reverse DCF implies that free cash flow after stock pay grows 10.4% a year for ten years, using a 10.2% discount rate.

Merck delivered 3.2% annual growth on that measure over the last 10 years, compared with the TenQ check’s 3.6% bar, which moves the historical pace halfway toward 4%.

Value MRK on your own assumptions

What could change the story

• Merck’s dependence on Keytruda leaves its growth exposed to competing treatments, while pricing pressure and generic competition already affect mature products such as Januvia and Janumet.
• Clinical progress is uneven: the tulisokibart study in systemic sclerosis-associated interstitial lung disease missed its primary endpoint and will be discontinued.
• Total debt of $53.9 billion against $7.1 billion in cash and short-term investments makes financing costs important, and earnings interest coverage of 4.41 falls below TenQ’s 5.00 bar.
• Acquisition spending complicates the earnings picture: the Terns charge affected both GAAP and non-GAAP results, while non-tax-deductible acquisition charges underpin Merck’s expected 2026 non-GAAP tax rate of 35.0% to 36.0%.

What to watch next

• The next releases will test Merck’s raised 2026 sales outlook of $66.3 billion to $67.3 billion, which includes an approximately 1% foreign exchange benefit.
• Keytruda Qlex and Winrevair sales, alongside Lipfendra’s launch progress, will show whether newer products are expanding their contribution beyond the quarter to June 2026.
• Merck’s 2026 non-GAAP EPS outlook of $2.66 to $2.76 includes acquisition charges of $3.62 per share for Cidara and $2.31 per share for Terns, making the distinction between acquisition charges and operating performance important.
• Free cash flow relative to the $16.1 billion generated over the last twelve months, together with debt and interest expense, will show how the portfolio expansion is affecting financial flexibility.

Sources

• Merck's earnings release, filed with the SEC
• Its latest 10-Q or 10-K, for the risk factors
• The MRK stock report, for every figure and check